公开(公告)号：US11547743B2

公开(公告)日：2023-01-10

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US10537612B2

公开(公告)日：2020-01-21

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US20170189487A1

公开(公告)日：2017-07-06

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/02 ,  A61K47/18 ,  A61K9/19 ,  A61K47/26

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US11446358B2

公开(公告)日：2022-09-20

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.
The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.

公开(公告)号：US11324805B2

公开(公告)日：2022-05-10

申请号：US15305049

申请日：2015-04-24

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Ryo Ohori ,  Kanta Horie

IPC: A61K38/18 ,  A61K47/18 ,  A61K47/26 ,  A61K9/19 ,  A61K38/00 ,  A61K47/02

Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations.
The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.